UNRESECTABLE RECTAL ADENOCARCINOMA
Clinical trials for UNRESECTABLE RECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE RECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE RECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Tough-to-Treat colon cancer patients
Disease control OngoingThis early-stage trial is testing whether combining existing cancer drugs with a new experimental drug (LY3214996) can help control advanced colorectal cancer that has stopped responding to standard treatments. The study aims to find safe doses and see if these combinations can s…
Matched conditions: UNRESECTABLE RECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New Two-Drug attack on Tough-to-Treat colon cancer
Disease control OngoingThis study is testing a new two-drug combination for people with advanced colorectal cancer that has spread and is no longer responding to standard chemotherapy. The trial combines an experimental pill called SX-682, which aims to block tumor growth, with an existing immunotherap…
Matched conditions: UNRESECTABLE RECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Can an immunotherapy boost stop tough colon cancer?
Disease control OngoingThis study is for people with advanced colorectal cancer that has spread or cannot be removed by surgery and has a specific BRAF gene mutation. It tests if adding the immunotherapy drug nivolumab to two standard targeted drugs works better to control the cancer and stop it from g…
Matched conditions: UNRESECTABLE RECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New triple attack on tough colon cancer shows promise
Disease control OngoingThis study is testing a combination of three drugs (encorafenib, cetuximab, and nivolumab) for people with advanced colorectal cancer that has a specific BRAF gene mutation and has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the three dr…
Matched conditions: UNRESECTABLE RECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC